| Autor: |
Soputro NA; Glickman Urological & Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA., Ferguson EL; Glickman Urological & Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA., Ramos-Carpinteyro R; Glickman Urological & Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA., Chavali JS; Glickman Urological & Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA., Geskin A; Glickman Urological & Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA., Fareed K; Glickman Urological & Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA., Berglund R; Glickman Urological & Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA., Fergany AF; Glickman Urological & Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA., Stein RJ; Glickman Urological & Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA., Haber GP; Glickman Urological & Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA., Campbell SC; Glickman Urological & Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA., Weight CJ; Glickman Urological & Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA., Kaouk JH; Glickman Urological & Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA. |
| Abstrakt: |
Objective: To evaluate the long-term functional and oncologic outcomes after robotic partial nephrectomy (RAPN) and radical nephrectomy (RARN). Materials and Methods: A retrospective review was performed on 1816 patients who underwent RAPN and RARN at our institution between January 2006 and January 2018. Patients with long-term follow-ups of at least 5 years were selected. Exclusion criteria included patients with a previous history of partial or radical nephrectomy, known genetic mutations, and whose procedures were performed for benign indications. Statistical analysis was performed with results as presented. Results: A total of 769 and 142 patients who underwent RAPN and RARN, respectively, met our inclusion criteria. The duration of follow-up was similar after the two procedures with a median of ∼100 months. The 5- and 10-year chronic kidney disease (CKD) upstaging-free survivals were 74.5% and 65.9% after RAPN and 53% and 46.4% after RARN, respectively. Older age was identified as a potential predictor for CKD progression after RARN, whereas older age, higher body mass index, baseline renal function, and ischemia time were shown to predict CKD progression after RAPN. Renal cell carcinoma-related mortality rates for RAPN and RARN were equally 1.1%. No statistically significant differences were identified in the local recurrence, metastatic, and disease-specific survival between the two procedures. Conclusion: Compared with RARN, RAPN conferred a better CKD progression-free survival. Several factors were identified as potential predictors for clinically significant CKD progression both in the early and late postoperative phase. Long-term oncologic outcomes between the two procedures remained similarly favorable. |
